PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia
Gamma delta (γδ) T-cell based immunotherapy is a promising concept for the treatment of hematologic malignancies. Not only in vitro but also in early phase clinical trials, zoledronic acid (Zol) and interleukin-2 (IL-2) have been successfully used to activate human γδ T-cells and to induce clinical...
Main Authors: | Timm Hoeres, Elisabeth Holzmann, Manfred Smetak, Josef Birkmann, Martin Wilhelm |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-03-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1550618 |
Similar Items
-
Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
by: Timm Hoeres, et al.
Published: (2018-04-01) -
An optimized cultivation method for future in vivo application of γδ T cells
by: Anna Bold, et al.
Published: (2023-07-01) -
Natural Self-Ligand Gamma Delta T Cell Receptors (γδTCRs) Insight: The Potential of Induced IgG
by: Thamires Rodrigues de Sousa, et al.
Published: (2020-08-01) -
Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes
by: Ruben Serrano, et al.
Published: (2020-03-01) -
Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy
by: Derek Lee, et al.
Published: (2022-06-01)